Skip to content
OpenCapital
Get started

Bicara Therapeutics BCAX Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value

Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value at other companies

Belden logo
BeldenBDC
$1.13M-20.8%
CHE
ChemedCHE
$4.55M-57.6%
HTF
Heartflow, Inc. Common StockHTFL
$12.2M+1,009%
KEE
Keel Infrastructure Corp. Common StockKEEL
$5.26M+279%
McCormick & Company, Incorporated logo
McCormick & Company, IncorporatedMKC
$4.6M+39.4%
Ametek logo
AmetekAME
$154.9M+32.2%

Other financials

Income statement

See full
Operating income-$60.2M-44.2%
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total debt$1.4M+144%
Total equity$514.0M+12.0%
Total assets$553.6M+15.8%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
CapEx$60.0K—
Free cash flow-$37.6M-33.7%

Valuation

See full
Market cap$1.64B+81.4%
Enterprise value$1.32B+288%

Returns & leverage

See full
Return on equity-32.3%—
Debt / equity0×0.0×
Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's share based compensation arrangement by share based payment award options exercises in period total intrinsic value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bicara Therapeutics's share based compensation arrangement by share based payment award options exercises in period total intrinsic value?
Bicara Therapeutics (BCAX) reported share based compensation arrangement by share based payment award options exercises in period total intrinsic value of $5.1M in Q1 2026.
How has Bicara Therapeutics's share based compensation arrangement by share based payment award options exercises in period total intrinsic value changed year-over-year?
Bicara Therapeutics's share based compensation arrangement by share based payment award options exercises in period total intrinsic value increased by 750.0% year-over-year, from $600K to $5.1M.
What does share based compensation arrangement by share based payment award options exercises in period total intrinsic value mean?
This represents the total aggregate intrinsic value realized by employees or directors upon the exercise of stock options during the period. It is calculated as the difference between the market price of the stock at the time of exercise and the exercise price of the options. This serves as a measure of the realized compensation value delivered to participants through equity incentives.